PDL1 Regulation by p53 via miR-34

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Cortez, Maria Angelica ^a   Ivan, Cristina ^a   Valdecanas, David ^a   Wang, Xiaohong ^a   Peltier, Heidi J ^b   Ye, Yuping ^a   Araujo, Luiz ^c   Carbone, David P ^c   Shilo, Konstantin ^c   Giri, Dipak K ^d   Kelnar, Kevin ^b   Martin, Desiree ^b   Komaki, Ritsuko ^a   Gomez, Daniel R ^a   Krishnan, Sunil ^a   Calin, George A ^a   Bader, Andreas G ^b   Welsh, James W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SYNLOGIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Texas Veterinary Pathology Associates (Houston)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LIPOSOME; MICRORNA 34A; PONASTERONE A; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; CD274 PROTEIN, HUMAN; CD8 ANTIGEN; MICRORNA; MIRN34 MICRORNA, MOUSE;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HCT116 CELL LINE; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; LUCIFERASE ASSAY; MACROPHAGE; MALE; MOLECULAR RECOGNITION; MOUSE; MOUSE MODEL; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ADENOCARCINOMA; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; METABOLISM; RADIATION RESPONSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD274; ANTIGENS, CD8; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; LIPOSOMES; LUNG NEOPLASMS; MICE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84956573071     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv303     Document Type: Article

References (56)

1. Pfeifer GP, Holmquist GP. Mutagenesis in the P53 gene. Biochim Biophys Acta. 1997;1333(1):M1-M8.
2. Elias J, Dimitrio L, Clairambault J, et al. The p53 protein and its molecular network: modelling a missing link between DNA damage and cell fate. Biochim Biophys Acta. 2014;1844(1 Pt B):232-247.
3. Rufini A, Tucci P, Celardo I, et al. Senescence and aging: the critical roles of p53. Oncogene. 2013;32(43):5129-5143.
4. Mollereau B, Ma D. The p53 control of apoptosis and proliferation: lessons from Drosophila. Apoptosis. 2014;19(10):1421-1429.
5. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-660.
6. Menendez D, Shatz M, Azzam K, et al. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet. 2011;7(3):e1001360.
7. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012;72(16):3948-3957.
8. Porta C, Hadj-Slimane R, Nejmeddine M, et al. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene. 2005;24(4):605-615.
9. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424(6948):516-523.
10. Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012;72(2):460-471.
11. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-414.
12. Lin L, Hou J, Ma F, et al. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol. 2013;191(7):3896-3904.
13. Swaminathan S, Suzuki K, Seddiki N, et al. Differential regulation of the Let-7 family of microRNAs in CD4+ T-cells alters IL-10 expression. J Immunol. 2012;188(12):6238-6246.
14. Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011;208(5):875-883.
15. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via micro-RNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.
16. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587.
17. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
18. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293-12297.
19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
20. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
22. Kelnar K, Peltier HJ, Leatherbury N, et al. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem. 2014;86(3):1534-1542.
23. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70(14):5923-5930.
24. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
25. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23(18):2140-2151.
26. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282(5393):1497-1501.
27. Sah NK, Munshi A, Nishikawa T, et al. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther. 2003;2(11):1223-1231.
28. Nakamura S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol. 2000;20(24):9391-9398.
29. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
30. Stark AM, Pfannenschmidt S, Tscheslog H, et al. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Neurol Res. 2006;28(8):787-793.
31. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19(6):607-614.
32. Dweep H, Sticht C, Pandey P, et al. miRWalk-Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011;44(5):839-847.
33. Mestdagh P, Lefever S, Pattyn F, et al. The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Res. 2011;39(20):e136.
34. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol. 1999;216(2):671-680.
35. Seggerson K, Tang L, Moss EG. Two genetic circuits repress the Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. Dev Biol. 2002;243(2):215-225.
36. Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58-63.
37. Cortez MA, Valdecanas D, Zhang X, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494-1503.
38. Stalder L, Heusermann W, Sokol L, et al. The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J. 2013;32(8):1115-1127.
39. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15(1):927-943.
40. Textor S, Fiegler N, Arnold A, et al. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011;71(18):5998-6009.
41. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130-1134.
42. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745-752.
43. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6(13):1586-1593.
44. Yang P, Li QJ, Feng Y, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291-303.
45. Shin J, Xie D, Zhong XP. MicroRNA-34a enhances T-cell activation by targeting diacylglycerol kinase zeta. PLoS One. 2013;8(10):e77983.
46. Wang X, Li J, Dong K, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27(3):443-452.
47. Wherry EJ. T-cell exhaustion. Nat Immunol. 2011;12(6):492-499.
48. Blackburn SD, Shin H, Freeman GJ, et al. Selective expansion of a subset of exhausted CD8 T-cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105(39):15016-15021.
49. Ha SJ, Mueller SN, Wherry EJ, et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med. 2008;205(3):543-555.
50. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T-cells during chronic viral infection. Nature. 2006;439(7077):682-687.
51. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T-cell responses in vitro. Int J Cancer. 2006;119(2):317-327.
52. Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7(5):389-395.
53. Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T-cells. Int Immunol. 2009;21(9):1065-1077.
54. Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009;35(4):741-749.
55. Riepsaame J, van Oudenaren A, den Broeder BJ, et al. MicroRNA-Mediated Down-Regulation of M-CSF Receptor Contributes to Maturation of Mouse Monocyte-Derived Dendritic Cells. Front Immunol. 2013;4:353.
56. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-859.